Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ZCEIQ
ADC Name	Ab4-AM1 D265C.LALA.H436A
Synonyms	Ab4-AM1 D265C.LALA.H436A Click to Show/Hide
Organization	Vor Biopharma Inec.
Drug Status	Investigative
Antibody Name	undisclosed
Antigen Name	Receptor-type tyrosine-protein phosphatase C (PTPRC)	Antigen Info
Payload Name	Undisclosed
Therapeutic Target	Stimulator of interferon genes protein (STING1)	Target Info
Linker Name	Undisclosed

General Information of The ADMET Data Related to This ADC(2027 Update)

Absorption

Click To Hide/Show 3 Absorption Data Related to This Level

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	96.6	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Maximum Observed Concentration (C_max)	16.5	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Time to Maximum Concentration (T_max)	0.083	hr	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

Distribution

Click To Hide/Show 2 Distribution Data Related to This Level

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	96.6	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Volume of Distribution (V_d)	54.3	mL/kg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

Metabolism

Click To Hide/Show 1 Metabolism Data Related to This Level

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	96.6	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

Excretion

Click To Hide/Show 3 Excretion Data Related to This Level

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	96.6	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Elimination Half-Life (t_1/2)	3.21	hr	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Clearance (CL)	10.4	mL/hr/kg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal inhibitory Concentration (IC50)	0.026	nM	CVCL_1650	B acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50)	0.28	nM	CVCL_1650	B acute lymphoblastic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.026 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.28 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

References

Ref 1	Anti-CD45 antibodies and conjugates thereof